ライフサイエンスコーパス: non-alcoholic fatty liver

1 tors to diseases like obesity, diabetes, and non-alcoholic fatty liver.

2 may be a cryptic co-factor in some cases of non-alcoholic fatty liver.

3 es was significantly higher in patients with non-alcoholic fatty liver.

4 severity of liver steatosis in subjects with non-alcoholic fatty liver.

5 markers of oxidative stress in subjects with non-alcoholic fatty liver.

6 iso-PGF2alpha were independent predictors of non-alcoholic fatty liver and a strong association of ur

7 of oxidative stress markers in patients with non-alcoholic fatty liver and no study has been performe

8 ar disease, type 2 diabetes, atherosclerosis,non-alcoholic fatty liver, and cancer.

9 tokine fetuin-A may impair renal function in non alcoholic fatty liver disease (NAFLD) by altering in

10 Participants with non-alcoholic fatty liver disease (defined as (1)H magne

11 HSCs and in a human cohort of subjects with non-alcoholic fatty liver disease (N = 146).

12 sis models (n = 3-5) and in human samples of non-alcoholic fatty liver disease (NAFLD) (n = 72-135).

13 Non-alcoholic fatty liver disease (NAFLD) affects a larg

14 Non-alcoholic fatty liver disease (NAFLD) and cardiovasc

15 the gut microbiota in choline deficiency in non-alcoholic fatty liver disease (NAFLD) and insulin re

16 Non-alcoholic fatty liver disease (NAFLD) and its more s

17 e similar to those observed in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoho

18 he serum XPO4 pattern in a broad spectrum of non-alcoholic fatty liver disease (NAFLD) cases.

19 Non-alcoholic fatty liver disease (NAFLD) characterizes

20 afer and more effective hepatitis C therapy, non-alcoholic fatty liver disease (NAFLD) could soon eme

21 The approach was developed on a non-alcoholic fatty liver disease (NAFLD) data set.

22 e a non-invasive fibrosis scoring system for non-alcoholic fatty liver disease (NAFLD) derived from r

23 Non-alcoholic fatty liver disease (NAFLD) has been recen

24 on liver function in bariatric patients with non-alcoholic fatty liver disease (NAFLD) in a randomize

25 Recent studies have raised the concept that non-alcoholic fatty liver disease (NAFLD) in adults is d

26 Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients wi

27 The incidence of non-alcoholic fatty liver disease (NAFLD) increases with

28 Non-alcoholic fatty liver disease (NAFLD) is a common me

29 Non-alcoholic fatty liver disease (NAFLD) is a major ris

30 Non-alcoholic fatty liver disease (NAFLD) is an increasi

31 Non-alcoholic fatty liver disease (NAFLD) is becoming th

32 Non-alcoholic fatty liver disease (NAFLD) is defined as

33 of the gut microbiome in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is emerging.

34 Non-alcoholic fatty liver disease (NAFLD) is one of the

35 Non-alcoholic fatty liver disease (NAFLD) is one of the

36 Non-alcoholic fatty liver disease (NAFLD) is one of the

37 The prevailing theory in non-alcoholic fatty liver disease (NAFLD) is the "two-hi

38 Non-alcoholic fatty liver disease (NAFLD) is the hepatic

39 Non-alcoholic fatty liver disease (NAFLD) is the most co

40 Non-alcoholic fatty liver disease (NAFLD) is the most co

41 ociated genes in the gastric tissue of obese non-alcoholic fatty liver disease (NAFLD) patients.

42 Non-alcoholic fatty liver disease (NAFLD) represents a s

43 The process initiates with non-alcoholic fatty liver disease (NAFLD) that progresse

44 Increasing evidence connects non-alcoholic fatty liver disease (NAFLD) to CKD.

45 tors FXR and CAR in disease progression from non-alcoholic fatty liver disease (NAFLD) to HCC.

46 There is no licensed treatment for non-alcoholic fatty liver disease (NAFLD), a condition t

47 -2006), overweight children with and without non-alcoholic fatty liver disease (NAFLD), and children

48 t only affected by the metabolic syndrome as non-alcoholic fatty liver disease (NAFLD), but may contr

49 yndrome (PCOS) is frequently associated with non-alcoholic fatty liver disease (NAFLD), but the mecha

50 d autophagy is associated with steatosis and non-alcoholic fatty liver disease (NAFLD), however the m

51 In non-alcoholic fatty liver disease (NAFLD), lipid build-u

52 blood spot testing-is often misdiagnosed as non-alcoholic fatty liver disease (NAFLD), non-alcoholic

53 with chronic hepatitis B (CHB) and 488 with non-alcoholic fatty liver disease (NAFLD), those with rs

54 biting recessive male-specific lethality and non-alcoholic fatty liver disease (NAFLD), which coincid

55 Non-alcoholic fatty liver disease (NAFLD), which include

56 caemic control in pre-diabetic patients with non-alcoholic fatty liver disease (NAFLD).

57 d increased oxidative damage are features of non-alcoholic fatty liver disease (NAFLD).

58 protein F (APO-F), a potential biomarker for non-alcoholic fatty liver disease (NAFLD).

59 chanisms differ in drug induced (DIS) and/or non-alcoholic fatty liver disease (NAFLD).

60 d increased oxidative damage are features of non-alcoholic fatty liver disease (NAFLD).

61 ged as a potential plasma marker to diagnose non-alcoholic fatty liver disease (NAFLD).

62 e (BBR) is beneficial for obesity-associated non-alcoholic fatty liver disease (NAFLD).

63 efficacy of sevelamer in treating mice with non-alcoholic fatty liver disease (NAFLD).

64 Visceral obesity is often accompanied by non-alcoholic fatty liver disease (NAFLD).

65 c steatosis both in an inbred mouse model of non-alcoholic fatty liver disease (SJL/J) and in a human

66 red liver histology defined as a decrease in non-alcoholic fatty liver disease activity score by at l

67 ntent), as well as elevated inflammation and non-alcoholic fatty liver disease activity scores, and h

68 in both the metabolic syndrome accompanying non-alcoholic fatty liver disease and cellular apoptosis

69 Increases in non-alcoholic fatty liver disease and drug-induced hepat

70 Non-alcoholic fatty liver disease and early fibrosis wer

71 Non-alcoholic fatty liver disease and its downstream seq

72 wed a substantial overlap with biomarkers of non-alcoholic fatty liver disease and its progression to

73 ACT: Low aerobic capacity increases risk for non-alcoholic fatty liver disease and liver-related dise

74 plasma lipoprotein metabolism, alcoholic and non-alcoholic fatty liver disease and myocardial infarct

75 ht to be of relevance for the development of non-alcoholic fatty liver disease and obesity.

76 y for treating inflammatory diseases such as non-alcoholic fatty liver disease and type 2 diabetes.

77 ute to various metabolic diseases, including non-alcoholic fatty liver disease and type 2 diabetes.

78 ism could alleviate the related epidemics of non-alcoholic fatty liver disease and type 2 diabetes.

79 Ninety four eligible patients who have non-alcoholic fatty liver disease and who are insulin re

80 complications such as insulin resistance and non-alcoholic fatty liver disease are reaching epidemic

81 , GLUT2 may contribute to the development of non-alcoholic fatty liver disease by facilitating the up

82 ein 5 in vivo prior to or after establishing non-alcoholic fatty liver disease in mice.

83 ivity, and prevents metabolic stress-induced non-alcoholic fatty liver disease in mice.

84 tic fat accumulation and provides a model of non-alcoholic fatty liver disease in which to study the

85 Non-alcoholic fatty liver disease is a serious health pr

86 mmation and fibrosis in humans and mice with non-alcoholic fatty liver disease is accompanied by accu

87 Non-alcoholic fatty liver disease is associated with hep

88 Non-alcoholic fatty liver disease is associated with mul

89 Steatohepatitis due to non-alcoholic fatty liver disease is developing into a n

90 The prevalence of non-alcoholic fatty liver disease is increasing worldwid

91 Non-alcoholic fatty liver disease is the most rapidly gr

92 The progressive non-alcoholic fatty liver disease observed in the LCR ra

93 besity, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and cancer.

94 bowel syndrome, and metabolic (i.e. obesity, non-alcoholic fatty liver disease, and diabetes) and neu

95 mote progression of alcoholic liver disease, non-alcoholic fatty liver disease, and non-alcoholic ste

96 ns or rodents to high-calorie diets promotes non-alcoholic fatty liver disease, characterized by neut

97 sis of several metabolic diseases, including non-alcoholic fatty liver disease, diabetes mellitus, an

98 with risk factors of liver disease, such as non-alcoholic fatty liver disease, hazardous alcohol use

99 at diet (HFD) consumption is associated with non-alcoholic fatty liver disease, increased apoptosis,

100 y and progression of liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatoh

101 was also able to reverse already established non-alcoholic fatty liver disease, resulting in signific

102 Non-alcoholic fatty liver disease, the most prevalent li

103 factors contributing to the pathogenesis of non-alcoholic fatty liver disease, we examined liver ste

104 type 2 diabetes mellitus has been linked to non-alcoholic fatty liver disease, which can progress to

105 tabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease.

106 erglycaemic, hyperinsulinaemic and developed non-alcoholic fatty liver disease.

107 hepatitis C and emergence of cirrhosis from non-alcoholic fatty liver disease.

108 ovel therapeutic target for diseases such as non-alcoholic fatty liver disease.

109 potential to treat both atherosclerosis and non-alcoholic fatty liver disease.

110 present a novel avenue for the treatment of non-alcoholic fatty liver disease.

111 ch probably increasing the susceptibility to non-alcoholic fatty liver disease.

112 and concomitant protection from diet-induced non-alcoholic fatty liver disease.

113 and hepatocyte lipoapoptosis are features of non-alcoholic fatty liver disease.

114 f metabolic conditions including obesity and non-alcoholic fatty liver disease.

115 ased atherosclerosis, increased obesity, and non-alcoholic fatty liver disease.

116 ages might be a novel therapeutic target for non-alcoholic fatty liver disease.

117 t CaMKK2 function confers protection against non-alcoholic fatty liver disease.

118 been implicated in fatty liver formation in non-alcoholic fatty liver disease.

119 BP-regulated de novo lipogenesis involved in non-alcoholic fatty liver disease.

120 provide unique targets for the treatment of non-alcoholic fatty liver disease.

121 lly therapeutic role of PHLPP2 activators in non-alcoholic fatty liver disease.

122 and metabolic outcomes in participants with non-alcoholic fatty liver disease.

123 function in other hepatic diseases, such as non-alcoholic fatty liver disease.

124 have liver fibrosis, mostly associated with non-alcoholic fatty liver disease.

125 n that causes insulin-resistant diabetes and non-alcoholic fatty liver disease.

126 eatures of the metabolic syndrome, including non-alcoholic fatty liver disease.

127 ecies (ROS) contribute to the development of non-alcoholic fatty liver disease.

128 be a promising approach for the treatment of non-alcoholic fatty liver disease.

129 type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.

130 etes, atherosclerotic vascular diseases, and non-alcoholic fatty liver disease.

131 nisms responsible for disease progression in non-alcoholic fatty liver disease.

132 ity, adipocyte hypertrophy, and present with non-alcoholic fatty liver disease; 3) DKO mice demonstra

133 Patients with non-alcoholic fatty liver had higher (p < 0.001) mean va